Oligonucleotide-Based Gene Therapy for Cardiovascular Disease
暂无分享,去创建一个
Y. Taniyama | K. Matsumoto | T. Ogihara | R. Morishita | J. Higaki | N. Tomita | A. Moriguchi | K. Yamamoto | H. Matsushita | Kei Yamamoto | H. Nakagami
[1] E. Nabel,et al. Gene therapy for cardiovascular diseases , 1999, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.
[2] T. Ogihara,et al. Application of transcription factor "decoy" strategy as means of gene therapy and study of gene expression in cardiovascular disease. , 1998, Circulation research.
[3] Y. Kaneda,et al. A novel strategy for myocardial protection using in vivo transfection of cis element 'decoy' against NFkappaB binding site: evidence for a role of NFkappaB in ischemia-reperfusion injury. , 1997, Circulation.
[4] M. Borger,et al. Coronary artery bypass grafting in patients with non-dialysis-dependent renal insufficiency. , 1997, Circulation.
[5] T. Ogihara,et al. Molecular Delivery System for Antisense Oligonucleotides: Enhanced Effectiveness of Antisense Oligonucleotides by HVJ-liposome Mediated Transfer , 1997, Journal of cardiovascular pharmacology and therapeutics.
[6] J. Isner. Oligonucleotide therapeutics — Novel cardiovascular targets , 1997, Nature Medicine.
[7] M. Aoki,et al. Prevention of graft coronary arteriosclerosis by antisense cdk2 kinase oligonucleotide , 1997, Nature Medicine.
[8] T. Ogihara,et al. In vivo transfection of cis element “decoy” against nuclear factor- κB binding site prevents myocardial infarction , 1997, Nature Medicine.
[9] D. Kornbrust,et al. Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys. , 1997, Toxicology.
[10] M. Pangburn,et al. Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action. , 1997, The Journal of pharmacology and experimental therapeutics.
[11] P. Tsao,et al. Cell cycle inhibition preserves endothelial function in genetically engineered rabbit vein grafts. , 1997, The Journal of clinical investigation.
[12] S. Crooke,et al. Progress in antisense therapeutics , 1996, Medicinal research reviews.
[13] M. Aoki,et al. Role of transcriptional cis-elements, angiotensinogen gene-activating elements, of angiotensinogen gene in blood pressure regulation. , 1996, Hypertension.
[14] L. Benimetskaya,et al. Multiple mechanisms may contribute to the cellular anti-adhesive effects of phosphorothioate oligodeoxynucleotides. , 1996, Nucleic acids research.
[15] M Vapalahti,et al. [Human gene therapy]. , 1996, Duodecim; laaketieteellinen aikakauskirja.
[16] R. Morishita,et al. In vivo identification of a negative regulatory element in the mouse renin gene using direct gene transfer. , 1995, The Journal of clinical investigation.
[17] T. Ogihara,et al. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[18] P. Tsao,et al. Genetic engineering of vein grafts resistant to atherosclerosis. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[19] S. Ross,et al. The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[20] T. Ogihara,et al. [Gene therapy for cardiovascular disease]. , 1993, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.
[21] S. Wesselingh,et al. Cytokine mRNA expression in postischemic/reperfused myocardium. , 1995, The American journal of pathology.
[22] S. Srinivasan,et al. Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides , 1995, Journal of clinical laboratory analysis.
[23] M. Entman,et al. Interleukin-8 gene induction in the myocardium after ischemia and reperfusion in vivo. , 1995, The Journal of clinical investigation.
[24] T. Ogihara,et al. Pharmacokinetics of antisense oligodeoxyribonucleotides (cyclin B1 and CDC 2 kinase) in the vessel wall in vivo: enhanced therapeutic utility for restenosis by HVJ-liposome delivery. , 1994, Gene.
[25] J. Satriano,et al. Activation and attenuation of transcription factor NF-kB in mouse glomerular mesangial cells in response to tumor necrosis factor-alpha, immunoglobulin G, and adenosine 3':5'-cyclic monophosphate. Evidence for involvement of reactive oxygen species. , 1994, The Journal of clinical investigation.
[26] G. R. Dodge,et al. Transcatheter Delivery of c‐myc Antisense Oligomers Reduces Neointimal Formation in a Porcine Model of Coronary Artery Balloon Injury , 1994, Circulation.
[27] G. Gibbons,et al. The emerging concept of vascular remodeling. , 1994, The New England journal of medicine.
[28] T. Ogihara,et al. Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides. , 1994, The Journal of clinical investigation.
[29] G. Evan,et al. Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides. , 1994, The Journal of clinical investigation.
[30] M. Entman,et al. Adhesion Molecule-Dependent Cardiovascular Injury , 1994 .
[31] T. Ogihara,et al. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[32] Larry J. Smith,et al. Cardiovascular effects of a phosphorothioate oligonucleotide with sequence antisense to p53 in the conscious rhesus monkey , 1993 .
[33] J. Floege,et al. Factors involved in the regulation of mesangial cell proliferation in vitro and in vivo. , 1993, Kidney international. Supplement.
[34] E. Schulze-Lohoff,et al. Cytokines and mesangial cells. , 1993, Kidney international. Supplement.
[35] A. Ortiz,et al. Role of tumor necrosis factor-alpha in the pathogenesis of glomerular diseases. , 1993, Kidney international. Supplement.
[36] T. Ogihara,et al. Antisense oligonucleotides directed at cell cycle regulatory genes as strategy for restenosis therapy. , 1993, Transactions of the Association of American Physicians.
[37] Amyj . Williams,et al. Functional analysis of the human vascular cell adhesion molecule 1 promoter , 1992, The Journal of experimental medicine.
[38] D Schwartz,et al. A Cascade Model for Restenosis: A Special Case of Atherosclerosis Progression , 1992, Circulation.
[39] L. Orgel,et al. The stability of different forms of double-stranded decoy DNA in serum and nuclear extracts. , 1992, Nucleic acids research.
[40] J. Chow,et al. ICAM-1 expression in renal disease. , 1992, Journal of clinical pathology.
[41] Michael Simons,et al. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo , 1992, Nature.
[42] S. Weintraub,et al. Retinoblastoma protein switches the E2F site from positive to negative element , 1992, Nature.
[43] G. Montalescot,et al. Myocardial Viability in Patients With Q Wave Myocardial Infarction and No Residual Ischemia , 1992, Circulation.
[44] A. Miller,et al. Human gene therapy comes of age , 1992, Nature.
[45] M. Pagano,et al. Association of cdk2 kinase with the transcription factor E2F during S phase. , 1992, Science.
[46] D. Brennan,et al. Mesangial cell accessory functions: mediation by intercellular adhesion molecule-1. , 1990, Kidney international.
[47] G. Nabel,et al. Regulation of gene expression with double-stranded phosphorothioate oligonucleotides. , 1990, Science.
[48] T. Libermann,et al. Activation of interleukin-6 gene expression through the NF-kappa B transcription factor , 1990, Molecular and cellular biology.
[49] D. Baltimore,et al. NF-κB: A pleiotropic mediator of inducible and tissue-specific gene control , 1989, Cell.
[50] K. Iwai,et al. Increased expression of DNA cointroduced with nuclear protein in adult rat liver. , 1989, Science.
[51] M. Reidy,et al. Regulation of Smooth Muscle Cell Growth in Injured Artery , 1989, Journal of cardiovascular pharmacology.
[52] D. Baltimore,et al. NF-kappa B: a pleiotropic mediator of inducible and tissue-specific gene control. , 1989, Cell.
[53] C. Stein,et al. Oligodeoxynucleotides as inhibitors of gene expression: a review. , 1988, Cancer research.